13 results on '"Dominici, Massimo"'
Search Results
2. Future Perspectives of Exosomal Payload of miRNAs in Lung Cancer
- Author
-
Aramini, Beatrice, Masciale, Valentina, Grisendi, Giulia, Banchelli, Federico, D’Amico, Roberto, Dominici, Massimo, Haider, Khawaja Husnain, Gonzalez, Elio A. Prieto, Section editor, and Haider, Khawaja Husnain, editor
- Published
- 2022
- Full Text
- View/download PDF
3. Homologous Recombination Repair Deficiency in Metastatic Prostate Cancer: New Therapeutic Opportunities.
- Author
-
Piombino, Claudia, Pipitone, Stefania, Tonni, Elena, Mastrodomenico, Luciana, Oltrecolli, Marco, Tchawa, Cyrielle, Matranga, Rossana, Roccabruna, Sara, D'Agostino, Elisa, Pirola, Marta, Bacchelli, Francesca, Baldessari, Cinzia, Baschieri, Maria Cristina, Dominici, Massimo, Sabbatini, Roberto, and Vitale, Maria Giuseppa
- Subjects
HOMOLOGOUS recombination ,DNA repair ,PROSTATE cancer ,METASTASIS ,ANDROGEN receptors ,CLINICAL trials ,LUTEINIZING hormone releasing hormone - Abstract
More than 20% of metastatic prostate cancer carries genomic defects involving DNA damage repair pathways, mainly in homologous recombination repair-related genes. The recent approval of olaparib has paved the way to precision medicine for the treatment of metastatic prostate cancer with PARP inhibitors in this subset of patients, especially in the case of BRCA1 or BRCA2 pathogenic/likely pathogenic variants. In face of this new therapeutic opportunity, many issues remain unsolved. This narrative review aims to describe the relationship between homologous recombination repair deficiency and prostate cancer, the techniques used to determine homologous recombination repair status in prostate cancer, the crosstalk between homologous recombination repair and the androgen receptor pathway, the current evidence on PARP inhibitors activity in metastatic prostate cancer also in homologous recombination repair-proficient tumors, as well as emerging mechanisms of resistance to PARP inhibitors. The possibility of combination therapies including a PARP inhibitor is an attractive option, and more robust data are awaited from ongoing phase II and phase III trials outlined in this manuscript. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. De Novo Metastatic Prostate Cancer: Are We Moving toward a Personalized Treatment?
- Author
-
Piombino, Claudia, Oltrecolli, Marco, Tonni, Elena, Pirola, Marta, Matranga, Rossana, Baldessari, Cinza, Pipitone, Stefania, Dominici, Massimo, Sabbatini, Roberto, and Vitale, Maria Giuseppa
- Subjects
DRUG efficacy ,METASTASIS ,INDIVIDUALIZED medicine ,CASTRATION-resistant prostate cancer ,GENE expression profiling ,TUMOR markers ,IMMUNOTHERAPY ,ENZYME inhibitors - Abstract
Simple Summary: De novo metastatic hormone-sensitive prostate cancer usually has a dismal prognosis, which has slightly improved in recent years thanks to the introduction of new hormonal agents and chemotherapy combined with androgen deprivation therapy from the first-line setting. The randomized clinical trials that have furnished the current therapeutic options stratified patients according to clinical criteria that do not necessarily reflect the biological rationale of the chosen therapy. With the accumulation of data on genomic features and transcriptomic profiling, several ongoing clinical trials are investigating new therapeutic approaches and the efficacy of a biomarker-guided treatment with the aim of defining a personalized treatment for de novo metastatic hormone-sensitive prostate cancer. De novo metastatic hormone-sensitive PC (mHSPC) accounts for 5–10% of all prostate cancer (PC) diagnoses but it is responsible for nearly 50% of PC-related deaths. Since 2015, the prognosis of mHSPC has slightly improved thanks to the introduction of new hormonal agents and chemotherapy combined with androgen deprivation therapy from the first-line setting. This review describes the current therapeutic opportunities for de novo mHSPC, focusing on potential molecular biomarkers identified in the main clinical trials that have modified the standard of care, the genomic features of de novo mHSPC, and the principal ongoing trials that are investigating new therapeutic approaches and the efficacy of a biomarker-guided treatment in this setting. The road toward personalized treatment for de novo mHSPC is still long, considering that the randomized clinical trials, which have furnished the basis of the current therapeutic options, stratified patients according to clinical criteria that did not necessarily reflect the biological rationale of the chosen therapy. The role of transcriptomic profiling of mHSPC as a predictive biomarker requires further validation, and it remains to be ascertained how the genomic variants detected in mHSPC, which are regarded as predictive in the castration-resistant disease, can be exploited in the mHSPC setting. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Early Onset Metastatic Colorectal Cancer: Current Insights and Clinical Management of a Rising Condition.
- Author
-
Medici, Bianca, Riccò, Beatrice, Caffari, Eugenia, Zaniboni, Silvia, Salati, Massimiliano, Spallanzani, Andrea, Garajovà, Ingrid, Benatti, Stefania, Chiavelli, Chiara, Dominici, Massimo, and Gelsomino, Fabio
- Subjects
EARLY detection of cancer ,METASTASIS ,POPULATION geography ,DISEASE incidence ,COLORECTAL cancer ,DISEASE risk factors - Abstract
Simple Summary: In this review, the authors will discuss the highlights of early onset colon cancer (EOCRC), an increasing but still unclear phenomenon. Indeed, the risk factors are largely similar to classic colon cancer (CRC), but it is still unclear what causes an increased risk of CRC at an early age. In addition, the issue of screening, which allows early diagnosis of the disease, is also important; the younger segment of the population is not included in such programs except if they belong to the highest-risk groups. If the phenomenon of EOCRC becomes more prominent, screening programs will have to be reviewed but with consideration of the consequences for health economics. In this review, we will focus on the epidemiological, prognostic, clinico-pathological, molecular, and therapeutic features of EOCRC; in particular, we will try to highlight the characteristics of the metastatic stage and the differences with CRC in older segments of the population. Despite a recent overall decrease in colorectal cancer (CRC) incidence and mortality, there has been a significant rise in CRC diagnoses in young adults. Early onset colorectal cancer (EOCRC) is defined as CRC diagnosed before the age of 50. Possible predisposing conditions include not only genetic syndromes but also other risk factors, such as microbiome alteration, antibiotic exposure, obesity, diabetes mellitus, and inflammatory bowel disease. EOCRC tends to be diagnosed later than in the older counterpart because of a lack of awareness and the fact that screening for CRC usually starts at the age of 50. Furthermore, CRC in young adults seems to be related to unique molecular features and more aggressive clinical behavior. This paper aims to provide an in-depth review of this poorly understood subject, with a comprehensive review of the state of the art and considerations for future perspectives. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Oropharyngeal squamous cell carcinoma: Prognostic factors for development of distant metastases and oncological outcomes.
- Author
-
Mattioli, Francesco, Lo Manto, Alfredo, Miglio, Matteo, Serafini, Edoardo, Rossi, Davide, Valerini, Sara, Tonelli, Roberto, Fermi, Matteo, Pugliese, Giuseppe, Bertolini, Federica, D'Angelo, Elisa, Depenni, Roberta, Dominici, Massimo, Lohr, Frank R. H., and Marchioni, Daniele
- Subjects
SQUAMOUS cell carcinoma ,PROGNOSIS ,SURVIVAL analysis (Biometry) ,OVERALL survival ,METASTASIS - Abstract
Background: Distant metastasis (DM) development in Oropharyngeal Squamous Cell Carcinoma (OPSCC) represents an important prognostic factor. The identification of a phenotype of metastatic patients may better define therapeutic and follow‐up programs. Methods: We included 408 patients with OPSCC, non‐metastatic at the time of diagnosis, and treated with curative intent. The Overall Survival (OS) analyses were performed and the impact of developing DM on survival was analyzed through Cox proportional‐hazard regression model. Results: 57 (14%) patients develop DM. 302 (74%) were p16+ OPSCC and 35 of them experienced DM. Advanced clinical stage, smoking, p16‐status, response to primary treatment, and loco‐regional relapse influence the DM rate. Only in the p16+ group, DM onset results in a greater impact on OS (p < 0.0001). Lung metastases have a better OS compared to non‐pulmonary ones (p = 0.049). Conclusion: This retrospective study shows a possible stratification of OPSCC patients based on the risk of the development of DMs. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Bone Metastases and Health in Prostate Cancer: From Pathophysiology to Clinical Implications.
- Author
-
Baldessari, Cinzia, Pipitone, Stefania, Molinaro, Eleonora, Cerma, Krisida, Fanelli, Martina, Nasso, Cecilia, Oltrecolli, Marco, Pirola, Marta, D'Agostino, Elisa, Pugliese, Giuseppe, Cerri, Sara, Vitale, Maria Giuseppa, Madeo, Bruno, Dominici, Massimo, and Sabbatini, Roberto
- Subjects
RISK of metastasis ,MEN'S health ,OSTEOBLASTS ,METASTASIS ,BONE tumors ,RISK assessment ,CANCER patients ,QUALITY of life ,PROGRESSION-free survival ,PROSTATE tumors ,PHENOTYPES ,DISEASE risk factors - Abstract
Simple Summary: Bone metastases and health are crucial issues in prostate cancer patient management. The aim of our review was to describe the biology of bone metastases and their clinical implications in prostate cancer patients, and current therapeutic strategies. In addition, "bone health" should be evaluated and specific treatments considered. In this way, we aimed to attract attention to the risk of both "bad" bone health and bone metastasis, and also to the available care options for these patients. Clinically relevant bone metastases are a major cause of morbidity and mortality for prostate cancer patients. Distinct phenotypes are described: osteoblastic, the more common osteolytic and mixed. A molecular classification has been also proposed. Bone metastases start with the tropism of cancer cells to the bone through different multi-step tumor–host interactions, as described by the "metastatic cascade" model. Understanding these mechanisms, although far from being fully elucidated, could offer several potential targets for prevention and therapy. Moreover, the prognosis of patients is markedly influenced by skeletal-related events. They can be correlated not only with bone metastases, but also with "bad" bone health. There is a close correlation between osteoporosis—a skeletal disorder with decreased bone mass and qualitative alterations—and prostate cancer, in particular when treated with androgen deprivation therapy, a milestone in its treatment. Systemic treatments for prostate cancer, especially with the newest options, have improved the survival and quality of life of patients with respect to skeletal-related events; however, all patients should be evaluated for "bone health" and osteoporotic risk, both in the presence and in the absence of bone metastases. Treatment with bone-targeted therapies should be evaluated even in the absence of bone metastases, as described in special guidelines and according to a multidisciplinary evaluation. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Cancer Stem Cells (CSCs), Circulating Tumor Cells (CTCs) and Their Interplay with Cancer Associated Fibroblasts (CAFs): A New World of Targets and Treatments.
- Author
-
Aramini, Beatrice, Masciale, Valentina, Arienti, Chiara, Dominici, Massimo, Stella, Franco, Martinelli, Giovanni, and Fabbri, Francesco
- Subjects
CANCER chemotherapy ,FIBROBLASTS ,METASTASIS ,CELLULAR signal transduction ,TREATMENT effectiveness ,CANCER patients ,STEM cells ,TUMOR markers ,DRUG resistance in cancer cells - Abstract
Simple Summary: The world of small molecules in solid tumors as cancer stem cells (CSCs), circulating tumor cells (CTCs) and cancer-associated fibroblasts (CAFs) continues to be under-debated, but not of minor interest in recent decades. One of the main problems in regard to cancer is the development of tumor recurrence, even in the early stages, in addition to drug resistance and, consequently, ineffective or an incomplete response against the tumor. The findings behind this resistance are probably justified by the presence of small molecules such as CSCs, CTCs and CAFs connected with the tumor microenvironment, which may influence the aggressiveness and the metastatic process. The mechanisms, connections, and molecular pathways behind them are still unknown. Our review would like to represent an important step forward to highlight the roles of these molecules and the possible connections among them. The importance of defining new molecules to fight cancer is of significant interest to the scientific community. In particular, it has been shown that cancer stem cells (CSCs) are a small subpopulation of cells within tumors with capabilities of self-renewal, differentiation, and tumorigenicity; on the other side, circulating tumor cells (CTCs) seem to split away from the primary tumor and appear in the circulatory system as singular units or clusters. It is becoming more and more important to discover new biomarkers related to these populations of cells in combination to define the network among them and the tumor microenvironment. In particular, cancer-associated fibroblasts (CAFs) are a key component of the tumor microenvironment with different functions, including matrix deposition and remodeling, extensive reciprocal signaling interactions with cancer cells and crosstalk with immunity. The settings of new markers and the definition of the molecular connections may present new avenues, not only for fighting cancer but also for the definition of more tailored therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. Myocarditis and diaphragmatic rhabdomyolysis with respiratory failure in a patient with metastatic melanoma treated with Nivolumab.
- Author
-
Baldessari, Cinzia, Pugliese, Giuseppe, Venturelli, Marta, Greco, Stefano, Ferrara, Leonardo, Longo, Giuseppe, Dominici, Massimo, and Depenni, Roberta
- Subjects
ECHOCARDIOGRAPHY ,RHABDOMYOLYSIS ,ADRENOCORTICAL hormones ,RESPIRATORY insufficiency ,MELANOMA ,CARDIOMYOPATHIES ,METASTASIS ,DIAPHRAGM (Anatomy) ,MAGNETIC resonance imaging ,NIVOLUMAB ,PULMONARY function tests ,BLOOD testing ,ACUTE diseases ,HYPOKINESIA - Abstract
Introduction: Immunotherapy dramatically changed history of melanoma patients with a clinical benefit never seen before. Nevertheless, severe and unexpected adverse effects can occur, fortunately rarely. Case presentation: We reported the case of a 75-year-old male patient affected by metastatic melanoma who developed myocarditis and acute rhabdomyolysis with secondary diaphragmatic dysfunction and consequent pulmonary restrictive syndrome after Nivolumab monotherapy. Blood tests and ultrasonography of the diaphragm revealing left hypokinesis suggested a Nivolumab-related rhabdomyolysis, as an immune-mediated adverse event. The rhabdomylolysis involved the diaphragm with consequent diaphragmatic weakness and respiratory distress. Management & outcome: The patient had a slow but slight and progressive improvement of symptoms and vital signs post-treatment with high-dose corticosteroids. Discussion: With this case report, we want to highlight the importance of rapid recognition and treatment of rare and unexpected, but potential serious immune-related adverse events. These events might happen despite the remarkable clinical benefits of immune checkpoint inhibitors. We do not know which patients will benefit from these therapies and why, when and in which cases adverse event will occur: we must not lower our attention. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
10. Pazopanib-related secondary polycythemia in metastatic myxofibrosarcoma: A case report and review of the literature.
- Author
-
Fanelli, Martina, Caputo, Francesco, Cerma, Krisida, Gelsomino, Fabio, Bari, Alessia, Dominici, Massimo, and Pozzi, Samantha
- Subjects
DISEASE progression ,POLYCYTHEMIA vera ,HEMOGLOBINS ,HEMATOCRIT ,CANCER chemotherapy ,METASTASIS ,PROTEIN-tyrosine kinase inhibitors ,TREATMENT effectiveness ,SCAPULA ,ASPIRIN ,CONNECTIVE tissue tumors ,RARE diseases - Abstract
Introduction: Pazopanib, a tyrosine kinase inhibitor (TKI), is a standard treatment for various tumours, including metastatic non-adipocytic soft-tissue sarcomas. In literature, erythrocytosis has been described as a TKI-related condition. Case report: A 59-year-old man underwent surgical removal of a sub-scapular mass consistent with myxofibrosarcoma. After distant relapse, he first started chemotherapy, and then Pazopanib. He was found to have increased levels of hemoglobin (Hb) and hematocrit (Hct). He was asymphtomatic, with no history of pulmonary disease nor smoking habit. Erythropoietin (EPO) level was higher than normal. A polycythemia vera was ruled out. Management & outcome: The patient started a prophylactic therapy with lysine acetylsalicylate, and we observed a reduction of Hb, but not Hct. Due to disease progression, we interrupted Pazopanib. After a week from drug discontinuation, Hb levels got back to the normal range, Hct was lowering. We decided not to perform phlebotomy, considering the declining trend in Hb and Hct values and the absence of symptoms. Discussion: We postulated a Pazopanib-related secondary erythrocytosis, since Hb and Hct levels increased from baseline during treatment, then normalized when Pazopanib was discontinued. We used the Naranjo Nomogram to assess the correlation between the adverse effect and Pazopanib, the correlation was "Probable", a score of 5. To the best of our knowledge, this is the first case report of Pazopanib-related secondary polycythemia in a patient with sarcoma. It is important to pay attention to blood count and to any symptoms potentially related to erythrocytosis in patients treated with TKIs. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Dissecting Tumor Growth: The Role of Cancer Stem Cells in Drug Resistance and Recurrence.
- Author
-
Aramini, Beatrice, Masciale, Valentina, Grisendi, Giulia, Bertolini, Federica, Maur, Michela, Guaitoli, Giorgia, Chrystel, Isca, Morandi, Uliano, Stella, Franco, Dominici, Massimo, and Haider, Khawaja Husnain
- Subjects
CANCER invasiveness ,PHENOMENOLOGICAL biology ,CELL physiology ,NEUROPLASTICITY ,WNT proteins ,DISEASE relapse ,CELLULAR signal transduction ,STEM cells ,HEDGEHOG signaling proteins ,TUMOR markers ,DRUG resistance in cancer cells - Abstract
Simple Summary: Cancer is one of the most debated problems all over the world. Cancer stem cells are considered responsible of tumor initiation, metastasis, drug resistance, and recurrence. This subpopulation of cells has been found into the tumor bulk and showed the capacity to self-renew, differentiate, up to generate a new tumor. In the last decades, several studies have been set on the molecular mechanisms behind their specific characteristics as the Wnt/β-catenin signaling, Notch signaling, Hedgehog signaling, transcription factors, etc. The most powerful part of CSCs is represented by the niches as "promoter" of their self-renewal and "protector" from the common oncological treatment as chemotherapy and radiotherapy. In our review article we highlighted the primary mechanisms involved in CSC tumorigenesis for the setting of further targets to control the metastatic process. Emerging evidence suggests that a small subpopulation of cancer stem cells (CSCs) is responsible for initiation, progression, and metastasis cascade in tumors. CSCs share characteristics with normal stem cells, i.e., self-renewal and differentiation potential, suggesting that they can drive cancer progression. Consequently, targeting CSCs to prevent tumor growth or regrowth might offer a chance to lead the fight against cancer. CSCs create their niche, a specific area within tissue with a unique microenvironment that sustains their vital functions. Interactions between CSCs and their niches play a critical role in regulating CSCs' self-renewal and tumorigenesis. Differences observed in the frequency of CSCs, due to the phenotypic plasticity of many cancer cells, remain a challenge in cancer therapeutics, since CSCs can modulate their transcriptional activities into a more stem-like state to protect themselves from destruction. This plasticity represents an essential step for future therapeutic approaches. Regarding self-renewal, CSCs are modulated by the same molecular pathways found in normal stem cells, such as Wnt/β-catenin signaling, Notch signaling, and Hedgehog signaling. Another key characteristic of CSCs is their resistance to standard chemotherapy and radiotherapy treatments, due to their capacity to rest in a quiescent state. This review will analyze the primary mechanisms involved in CSC tumorigenesis, with particular attention to the roles of CSCs in tumor progression in benign and malignant diseases; and will examine future perspectives on the identification of new markers to better control tumorigenesis, as well as dissecting the metastasis process. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. The Release of Inflammatory Mediators from Acid-Stimulated Mesenchymal Stromal Cells Favours Tumour Invasiveness and Metastasis in Osteosarcoma.
- Author
-
Avnet, Sofia, Lemma, Silvia, Cortini, Margherita, Di Pompo, Gemma, Perut, Francesca, Lipreri, Maria Veronica, Roncuzzi, Laura, Columbaro, Marta, Errani, Costantino, Longhi, Alessandra, Zini, Nicoletta, Heymann, Dominique, Dominici, Massimo, Grisendi, Giulia, Golinelli, Giulia, Consolino, Lorena, Longo, Dario Livio, Nanni, Cristina, Righi, Alberto, and Baldini, Nicola
- Subjects
RISK of metastasis ,BIOLOGICAL models ,INTERLEUKINS ,XENOGRAFTS ,IN vivo studies ,OSTEOSARCOMA ,CANCER invasiveness ,ANIMAL experimentation ,RISK assessment ,STEM cells ,INFLAMMATORY mediators ,ACIDOSIS ,MICE ,GLYCOLYSIS ,DISEASE complications - Abstract
Simple Summary: We aimed to validate the correlation between tumour glycolysis/acidosis and inflammation in osteosarcoma-associated mesenchymal stromal cells and investigate the role of acidity-induced inflammation in the development of metastasis in this very aggressive cancer. We confirmed the presence of an acidic microenvironment in osteosarcoma xenografts, both subcutaneous and orthotopic, using state-of-the-art imaging technologies; corroborated the correlation between tumour glycolysis, acidosis, and inflammatory markers in human patients; and finally, explored the use of anti-IL6 antibody to target these pathogenic pathways, using advanced 3D microfluidic models. In the future, advanced imaging systems for the measurement of tumour glycolysis and/or pH may help identify osteosarcoma patients who would benefit from anti-IL6 therapies to complement conventional therapy. Osteosarcoma is the most frequent primary malignant bone tumour with an impressive tendency to metastasise. Highly proliferative tumour cells release a remarkable amount of protons into the extracellular space that activates the NF-kB inflammatory pathway in adjacent stromal cells. In this study, we further validated the correlation between tumour glycolysis/acidosis and its role in metastases. In patients, at diagnosis, we found high circulating levels of inflammatory mediators (IL6, IL8 and miR-136-5p-containing extracellular vesicles). IL6 serum levels significantly correlated with disease-free survival and
18 F-FDG PET/CT uptake, an indirect measurement of tumour glycolysis and, hence, of acidosis. In vivo subcutaneous and orthotopic models, co-injected with mesenchymal stromal (MSC) and osteosarcoma cells, formed an acidic tumour microenvironment (mean pH 6.86, as assessed by in vivo MRI-CEST pH imaging). In these xenografts, we enlightened the expression of both IL6 and the NF-kB complex subunit in stromal cells infiltrating the tumour acidic area. The co-injection with MSC also significantly increased lung metastases. Finally, by using 3D microfluidic models, we directly showed the promotion of osteosarcoma invasiveness by acidosis via IL6 and MSC. In conclusion, osteosarcoma-associated MSC react to intratumoural acidosis by triggering an inflammatory response that, in turn, promotes tumour invasiveness at the primary site toward metastasis development. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
13. Suppression of Invasion and Metastasis of Triple-Negative Breast Cancer Lines by Pharmacological or Genetic Inhibition of Slug Activity.
- Author
-
Ferrari-Amorotti, Giovanna, Chiodoni, Claudia, Fei Shen, Cattelani, Sara, Soliera, Angela Rachele, Manzotti, Gloria, Grisendi, Giulia, Dominici, Massimo, Rivasi, Francesco, Colombo, Mario Paolo, Fatatis, Alessandro, and Calabretta, Bruno
- Subjects
- *
TRANYLCYPROMINE , *TUMOR suppressor proteins , *METASTASIS , *TRIPLE-negative breast cancer , *CELL lines - Abstract
Most triple-negative breast cancers (TNBCs) exhibit gene expression patterns associated with epithelial-to-mesenchymal transition (EMT), a feature that correlates with a propensity for metastatic spread. Overexpression of the EMT regulator Slug is detected in basal and mesenchymal-type TNBCs and is associated with reduced E-cadherin expression and aggressive disease. The effects of Slug depend, in part, on the interaction of its N-terminal SNAG repressor domain with the chromatin-modifying protein lysine demethylase 1 (LSD1); thus, we investigated whether tranylcypromine [also known as trans-2-phenylcyclopropylamine hydrochloride (PCPA) or Parnate], an inhibitor of LSD1 that blocks its interaction with Slug, suppresses the migration, invasion, and metastatic spread of TNBC cell lines. We show here that PCPA treatment induces the expression of E-cadherin and other epithelial markers and markedly suppresses migration and invasion of TNBC cell lines MDA-MB-231 and BT-549. These effects were phenocopied by Slug or LSD1 silencing. In two models of orthotopic breast cancer, PCPA treatment reduced local tumor growth and the number of lung metastases. In mice injected directly in the blood circulation with MDA-MB-231 cells, PCPA treatment or Slug silencing markedly inhibited bone metastases but had no effect on lung infiltration. Thus, blocking Slug activity may suppress the metastatic spread of TNBC and, perhaps, specifically inhibit homing/colonization to the bone. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.